Bio-Rad and Seegene Enter into Partnership for Molecular Diagnostic Testing Products

Bio-Rad Laboratories (Hercules, CA, USA) and Seegene, Inc. (Seoul, Korea) have entered into a partnership for the clinical development and commercialization of infectious disease molecular diagnostic products.

Under the terms of the agreement, Seegene will provide diagnostic tests for use on Bio-Rad’s CFX96 Dx Real-Time PCR System for U.S. markets pending clinical development and clearance from the US Food & Drug Administration (FDA). Seegene assays offer multiplex real-time PCR detection and differentiation, with high sensitivity and specificity of up to seven targets in a single reaction. The assays deliver results in approximately four hours.

“We look forward to working with Seegene to provide needed diagnostic testing products to US markets,” said Dara Wright, Bio-Rad EVP and President, Clinical Diagnostics. “Seegene’s unique assay design, chemistries, and high-level multiplexing can detect multiple infectious disease targets simultaneously, making the assays well-suited for syndromic testing.”

Related Links:
Bio-Rad Laboratories
Seegene, Inc.